Product Compliance And Certification For Medical Device In South Korea

Scope and evidence must be confirmed before any paid tests or filings.

In South Korea, “medical device” is not a single certification route. First identify the actual intended use and MFDS product category; then separate the ordinary medical-device regime from in-vitro diagnostics (IVD), digital medical devices and any independently regulated radio equipment. A Class II label alone cannot settle the filing route.

Use this route map to decide what has to be established before a Korean importer commits to a filing, packaging run or first commercial shipment. It is not a classification decision for an unnamed product.

Classify the device, not its marketing name

For an internal decision record (not a statutory “signed-memo” formality), document these five facts before selecting notification, certification or approval:

Exact clinical purpose, user (professional or layperson), patient population, claims and instructions for use.
Korean MFDS item name/code and class under the current product-classification notice; do not copy an EU or US class.
In-vitro analysis of human- or animal-origin specimens, a software diagnostic or therapy function, AI, connectivity, or combination with a medicinal substance.
Invasiveness, implant/contact duration, energy delivered, sterility, reprocessing and accessories or modules sold together.
Comparison with Korean-cleared products: intended use, operating principle, relevant materials and performance; identify differences that could affect safety or efficacy.

Cross-regime decision matrix for a Korean launch

Product trigger	Regulatory layer / likely route	Decision that remains open
Ordinary low-risk device matching a notified Class I item	Medical Devices Act; usually Class I product notification.	Check the actual item code and any special exception; “low risk” by itself is insufficient.
Ordinary Class II item	Usually NIDS certification; certain Class II products instead require MFDS approval.	Substantial equivalence, novelty, clinical-report trigger and relevant product-specific rules.
Ordinary Class III or IV item	MFDS product approval and technical-document review.	What local safety, performance and clinical evidence is needed for this design?
Reagent, assay or analyser testing samples of human or animal origin outside the body	IVD-specific Act and MFDS notices; class and filing route require IVD classification.	Is it self-test or professional-use, and is usability evidence required? The 10 Aug 2026 IVD amendment needs checking.
Software or AI with a medical purpose, or ICT-enabled equipment potentially meeting the statutory definition of a digital medical device	Screen under the Digital Medical Products Act and its dedicated classification and permission rules, effective since 24 Jan 2025.	Which digital-device category and which product-version/change rules apply? Avoid relying solely on pre-2025 general software categories.
Device combined with a medicine or digital convergence drug	Check combination/product status and potentially the Pharmaceutical Affairs framework as well as device controls.	What is the principal therapeutic action, component role and applicable combined-product pathway?
Bluetooth, Wi-Fi or other communications hardware inside the device	MFDS device route plus a separate RRA radio/communications conformity-assessment screen, if the equipment is within scope.	Is the exact radio module/final equipment covered, already assessed, or exempt? An MFDS approval is not automatically an RRA clearance.

Digital Medical Products Act Articles 2 and 5 permit overlap with IVD products and refer to the ordinary device/IVD laws where not otherwise regulated. Software, a processor or a Bluetooth chip alone does not conclusively establish digital-device status. If the digital-device rules apply, check the Act’s deemed-authorisation provisions; do not plan duplicate approvals without first checking the legal interface.

The MFDS amendment of 10 August 2026 addresses usability submissions for self-testing IVD reagents and equipment and provides for possible evidence waivers under specified annexes. It is not a general usability-report requirement for every IVD product.

Match the evidence to the device’s actual risk

Device feature	Evidence to assemble / applicability test	Failure mode to prevent
Sterile or reusable contact device	Sterilisation or reprocessing validation, packaging, shelf life, biocompatibility where relevant.	Foreign certificates without device/model- and process-specific support.
Electrically powered monitoring or therapy	Electrical/mechanical safety, EMC and performance reports against applicable Korean requirements.	Assuming IEC or CE paperwork always satisfies Korean test specifications.
Implant or invasive device	Materials, risk analysis, durability and clinical justification proportionate to intended use.	Copying a predicate when the patient-contact mechanism differs.
Software or adaptive AI	Version/build identification, verification/validation, cybersecurity and update-control evidence as applicable.	Marketing an updated algorithm outside the reviewed product scope.
IVD self-test	Analytical/clinical performance as applicable, intended users, lay usability and Korean instructions.	Reusing only a professional-use validation for home users.
Wireless connected device	Radio equipment particulars and RRA applicability evidence alongside MFDS EMC/device work.	Confusing product safety evidence with communications conformity.

Who holds the Korean import route, and when KGMP matters

The importer undertaking the import business is subject to the Korean import-business permission framework, and product-specific import permission, certification or notification as applicable (Medical Devices Act, Article 15). Identify the licensed Korean applicant and the legal holder of each approval before signing distribution contracts. A foreign CE certificate does not replace Korean market entry.

KGMP is a separate quality-system workstream, not another name for product approval. MFDS published a February 2026 English compilation covering general, IVD and digital-device GMP standards. Confirm site, scope, inspection/document route and timing for the precise product; do not assume every Class I item has the same KGMP obligation as Class III. Detailed submission management belongs to the dedicated medical-device approval services in South Korea page.

Digital medical-device import permissions are also addressed specifically by Article 12 of the Digital Medical Products Act; verify the correct legal applicant and avoid assuming that the general Article 15 filing is an additional, duplicate approval.

Digital medical-device software requires a separate quality-system applicability check: Article 24 of the Digital Medical Products Act provides for certification against software quality-management standards, while Article 18(2) deems that certification satisfied if qualifying digital good-management-system certification has already been obtained. Do not budget for two independent certificates without checking that statutory interface.

Korean label, UDI and claim consistency

Before releasing artwork, reconcile the Korean product name, item/model codes, intended use, manufacturer/importer details, warnings, instructions, storage conditions and any date or lot information with the authorised/declared scope. Articles 20–22 of the Medical Devices Act govern container, outer-pack and package-insert information; MFDS also publishes separate labelling rules.

Check whether and how Korea’s UDI identification, marking and device-information requirements apply to the exact device, packaging level and supply model. Do not substitute a foreign UDI database record for a Korean applicability decision. For a connected device, track the hardware/software version on the label and in the technical file.

The Medical Devices Act expressly identifies core container information including the manufacturer/importer, origin for imports, Korean permission/certification/notification identification, lot or manufacturing data, the “medical device” designation and specified UDI or single-use indications. Article 22 controls package inserts, including when electronic media or a website may be used. Check the implementing exceptions before deciding that a particular item must appear on every package.

The ordinary device labelling checklist must not be applied unchanged to an IVD or digital medical-device software product. IVD Act Article 13 uses the designation “in vitro diagnostic medical device” instead of the ordinary “medical device” designation and adds intended-use and storage particulars, subject to implementing exceptions. Digital Medical Products Act Articles 21–22 set separate marking particulars for digital medical-device software, including version information and “for professional use only” when MFDS so designates. For ordinary devices and IVDs, website provision of an IFU is limited to MFDS-designated devices used mainly in medical institutions (Medical Devices Act Article 22(2); IVD Act Article 15(2)); a public website link is not an automatic substitute for a home-use paper/electronic insert. For software delivered without physical media, assess the Korean UDI notice’s post-installation display option rather than assuming a printed package.

Five release gates before the first commercial shipment

Treat each gate as a stop/go question. Passing one does not excuse a failure at the next.

Classification frozen: named product, Korean item code, risk class, IVD/digital/combination status and documented unresolved questions.
Applicant and scope frozen: licensed importer, manufacturing site, model family, intended use, accessories, relevant KGMP plan and approval ownership.
Evidence aligned: Korean test specifications, technical file, clinical/performance justification and any RRA/IVD/digital submissions or exclusions checked.
Artwork aligned: Korean label/IFU, claim boundaries, UDI applicability, version and importer details mapped to the filing.
Release authorised: required Korean product action completed, quality-system and parallel approvals addressed, import-clearance documents verified, complaint/recall roles assigned.

Changes that force a new regulatory check

Before a post-launch update, re-run classification and approval-scope checks for:

A new clinical claim, home-use indication, patient group or sample type.
A changed implant/contact material, sterilisation method, supplier site or manufacturing location.
A software model update, AI retraining, decision threshold, intended output or wireless hardware replacement.
A new importer, label, package level, model/accessory or Korean marketing claim; determine whether notification, change certification/approval or documented change control applies.

For a digital medical device, Article 11 distinguishes safety/efficacy-significant changes requiring an authorisation, certification or notification of change from other changes for which records must be kept and changes reported. Do not treat a “minor software update” as an automatic no-filing exception.

Adjacent markets and official verification

Do not transplant the outcome from a different country. The same manufacturer may need different product codes, local applicants and test evidence in the EU medical-device market and Singapore’s medical-device market. This page owns the Korean cross-regime decision; those pages own their respective markets.

Official sources to verify against the product version

The Korean original prevails over reference translations and explanatory web pages.

Check future amendments before submission; the 2026 notices cited here are date-specific.

Product-specific questions

Does a Korean Class II medical device always use NIDS certification?

No. MFDS describes certification for many Class II devices but approval for certain Class II categories, including novel or higher-evidence routes. Confirm the item code, equivalence and current MFDS notice.

Does a CE mark or FDA clearance exempt my imported device from Korean filing?

Do not assume it does. Korean import-business and product routes follow Korean law; overseas evidence may help the technical file, but neither foreign approval nor a distributor agreement automatically completes the Korean requirements.

Is a home-use IVD test treated like the same assay used only by a laboratory?

Not necessarily. Intended users and claims affect the IVD file. The MFDS amendment dated 10 August 2026 specifically addresses usability evidence for self-testing IVD products; assess the actual applicability and transitional terms.

Can I put an AI diagnostic app under the old generic software code?

Do not rely on that shortcut. The Digital Medical Products Act has operated since 24 January 2025 and MFDS published a revised digital permission notice on 27 July 2026. Classify the function and version under the current digital framework.

If MFDS approves a Bluetooth patient monitor, is radio compliance finished?

Not automatically. Check whether the complete radio equipment or module is covered by the separate RRA conformity-assessment regime and whether a recognised result or exemption actually applies.